- Home
- AMS vs MURA Comparison
AMS vs MURA Comparison
Compare AMS & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMS
- MURA
- Stock Information
- Founded
- AMS 1980
- MURA 2013
- Country
- AMS United States
- MURA Ireland
- Employees
- AMS N/A
- MURA N/A
- Industry
- AMS Medical Specialities
- MURA
- Sector
- AMS Health Care
- MURA
- Exchange
- AMS Nasdaq
- MURA Nasdaq
- Market Cap
- AMS 17.9M
- MURA 17.7M
- IPO Year
- AMS N/A
- MURA N/A
- Fundamental
- Price
- AMS $2.98
- MURA $2.56
- Analyst Decision
- AMS
- MURA Strong Buy
- Analyst Count
- AMS 0
- MURA 4
- Target Price
- AMS N/A
- MURA $13.00
- AVG Volume (30 Days)
- AMS 7.0K
- MURA 1.1M
- Earning Date
- AMS 05-15-2025
- MURA 05-20-2025
- Dividend Yield
- AMS N/A
- MURA N/A
- EPS Growth
- AMS 243.96
- MURA N/A
- EPS
- AMS 0.33
- MURA N/A
- Revenue
- AMS $28,340,000.00
- MURA N/A
- Revenue This Year
- AMS $23.63
- MURA $34.35
- Revenue Next Year
- AMS N/A
- MURA N/A
- P/E Ratio
- AMS $8.76
- MURA N/A
- Revenue Growth
- AMS 32.90
- MURA N/A
- 52 Week Low
- AMS $2.51
- MURA $0.95
- 52 Week High
- AMS $4.60
- MURA $4.74
- Technical
- Relative Strength Index (RSI)
- AMS 61.91
- MURA 53.24
- Support Level
- AMS $2.68
- MURA $2.48
- Resistance Level
- AMS $2.80
- MURA $2.72
- Average True Range (ATR)
- AMS 0.08
- MURA 0.10
- MACD
- AMS 0.02
- MURA 0.02
- Stochastic Oscillator
- AMS 94.12
- MURA 33.88
About AMS American Shared Hospital Services
American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates most of its revenue from the domestic market.
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.